Respiratory Test Kit Metrix® COVID / Flu Test 25 Tests
| MPN | 1271000 |
|---|---|
| Brand | McKesson |
| Packaging | KT/1 |
Note : Image shown for reference purposes only. Actual product appearance may vary. Please read product description for full and accurate details.
Features
- The Metrix COVID/Flu Test has been authorized for emergency use by FDA under an EUA: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2
- The Metrix® COVID/Flu Test is a reverse transcription and loop-mediated isothermal amplification (RT-LAMP) test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B nucleic acid
- This test is authorized for non-prescription home use with anterior nasal (AN) swab specimens from individuals aged 14 years or older (self-collected) or individuals aged 2 years or older (collected by an adult) with signs and symptoms of respiratory infection consistent with COVID-19
- The Metrix COVID/Flu Test is intended for use in the differential detection of SARS-CoV-2, influenza A, and influenza B nucleic acid in clinical specimens and is not intended to detect Influenza C. SARS-CoV-2, influenza A, and influenza B nucleic acid is generally detectable in anterior nasal swab specimens during the acute phase of infection
- Positive results indicate the presence of viral nucleic acid, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status
- Positive results do not rule out bacterial infection or co-infection with other pathogens not detected by the test
- Individuals who test positive with the Metrix COVID/Flu Test should self-isolate and seek follow up care with their physician or healthcare provider as additional testing may be necessary
- Negative results do not rule out SARS-CoV-2, influenza A, and/or influenza B infection and should not be used as the sole basis for treatment or other management decisions, including infection control decisions
- Negative results should be considered in the context of current prevalence of infection, an individual’s recent exposures, history and the presence of clinical signs and symptoms consistent with respiratory infection
- Requires the Metrix Reader (Gen 2) - sold separately
| McKesson # | 1271000 |
|---|---|
| Manufacturer # | MTRX-C19+FLU-25PK |
| Brand | Metrix® |
| Manufacturer | Sekisui Diagnostics |
| Country of Origin | Unknown |
| Application | Respiratory Test Kit |
| Buy American Act (BAA) Compliant | No |
| Contents 1 | (25) Caps, (25) Collectors, (25) Swabs, (25) Sensors, Test Instructions |
| For Use With | For Metrix Reader (Gen 2) |
| Number of Tests | 25 Tests |
| Product Dating | McKesson Acceptable Dating: we will ship >= 14 days |
| Purchase Program Type | Standard Purchase |
| Reading Type | Machine Read |
| Sample Type | Nasal Swab Sample |
| Specialty | Molecular |
| Test Format | Test Device Format |
| Test Kit Type | Rapid |
| Test Method | NAAT |
| Test Name | COVID / Flu Test |
| Test Type | RT-LAMP |
| Time to Results | 20 Minute Results |
| Trade Agreement Act (TAA) Compliant | No |
| UNSPSC Code | 41116205 |



